Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg
Christine I. Wooddell, Man‐Fung Yuen, Henry Lik‐Yuen Chan, et al.
Science Translational Medicine (2017) Vol. 9, Iss. 409
Open Access | Times Cited: 411

Showing 1-25 of 411 citing articles:

The current state and future directions of RNAi-based therapeutics
Ryan L. Setten, John J. Rossi, Si‐ping Han
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 6, pp. 421-446
Closed Access | Times Cited: 1184
Therapeutic siRNA: state of the art
Bo Hu, Liping Zhong, Yuhua Weng, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1111
Hepatitis B virus infection
Man‐Fung Yuen, Ding‐Shinn Chen, Geoffrey Dusheiko, et al.
Nature Reviews Disease Primers (2018) Vol. 4, Iss. 1
Closed Access | Times Cited: 680
Therapeutic strategies for hepatitis B virus infection: towards a cure
Gregory Fanning, Fabien Zoulim, Jinlin Hou, et al.
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 11, pp. 827-844
Closed Access | Times Cited: 467
A global scientific strategy to cure hepatitis B
Peter Revill, Francis V. Chisari, Joan M. Block, et al.
˜The œLancet. Gastroenterology & hepatology (2019) Vol. 4, Iss. 7, pp. 545-558
Open Access | Times Cited: 420
Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy
Mindie H. Nguyen, Grace Lai‐Hung Wong, Edward Gane, et al.
Clinical Microbiology Reviews (2020) Vol. 33, Iss. 2
Open Access | Times Cited: 420
Immunobiology and pathogenesis of hepatitis B virus infection
Matteo Iannacone, Luca G. Guidotti
Nature reviews. Immunology (2021) Vol. 22, Iss. 1, pp. 19-32
Closed Access | Times Cited: 345
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡
Markus Cornberg, Anna Suk‐Fong Lok, Norah A. Terrault, et al.
Journal of Hepatology (2019) Vol. 72, Iss. 3, pp. 539-557
Open Access | Times Cited: 292
Hepatitis B
Wen‐Juei Jeng, George Papatheodoridis, Anna S. Lok
The Lancet (2023) Vol. 401, Iss. 10381, pp. 1039-1052
Closed Access | Times Cited: 291
Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients
Barbara Testoni, Fanny Lebossé, Caroline Scholtès, et al.
Journal of Hepatology (2018) Vol. 70, Iss. 4, pp. 615-625
Open Access | Times Cited: 257
RNAi therapeutic and its innovative biotechnological evolution
Yuhua Weng, Haihua Xiao, Jinchao Zhang, et al.
Biotechnology Advances (2019) Vol. 37, Iss. 5, pp. 801-825
Closed Access | Times Cited: 250
Nucleic acid delivery for therapeutic applications
Akash Gupta, Jason L. Andresen, Rajith S. Manan, et al.
Advanced Drug Delivery Reviews (2021) Vol. 178, pp. 113834-113834
Closed Access | Times Cited: 225
Current Development of siRNA Bioconjugates: From Research to the Clinic
Ivan V. Chernikov, Valentin V. Vlassov, E. L. Chernolovskaya
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 193
Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease
Stephan Urban, Christoph Neumann‐Haefelin, Pietro Lampertico
Gut (2021) Vol. 70, Iss. 9, pp. 1782-1794
Open Access | Times Cited: 176
Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection
Shi Liu, Bin Zhou, Juan D. Valdes, et al.
Hepatology (2018) Vol. 69, Iss. 4, pp. 1816-1827
Open Access | Times Cited: 167
Role of Lipid-Based and Polymer-Based Non-Viral Vectors in Nucleic Acid Delivery for Next-Generation Gene Therapy
Aniket Wahane, Akaash Waghmode, Alexander Kapphahn, et al.
Molecules (2020) Vol. 25, Iss. 12, pp. 2866-2866
Open Access | Times Cited: 167
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
Man‐Fung Yuen, Seng Gee Lim, Robert Pleśniak, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 21, pp. 1957-1968
Open Access | Times Cited: 154
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Grace Lai‐Hung Wong, Ed Gane, Anna S. Lok
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1249-1262
Open Access | Times Cited: 149
Hepatitis B virus persistence and reactivation
Yu Shi, Min Zheng
BMJ (2020), pp. m2200-m2200
Open Access | Times Cited: 147
Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential
Yuchen Xia, Haitao Guo
Antiviral Research (2020) Vol. 180, pp. 104824-104824
Open Access | Times Cited: 144
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook
Anna Kramvis, Kyong‐Mi Chang, Maura Dandri, et al.
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 19, Iss. 11, pp. 727-745
Open Access | Times Cited: 117
Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial
Man‐Fung Yuen, Jeong Heo, Jeong-Won Jang, et al.
Nature Medicine (2021) Vol. 27, Iss. 10, pp. 1725-1734
Open Access | Times Cited: 115
Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections
María Guadalupe Martínez, Anders Boyd, Emmanuel Combe, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 3, pp. 706-717
Open Access | Times Cited: 110
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial
Heiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov, et al.
The Lancet Infectious Diseases (2022) Vol. 23, Iss. 1, pp. 117-129
Closed Access | Times Cited: 99
Hepatitis Virus and Hepatocellular Carcinoma: Recent Advances
Chen Shen, Xin Jiang, Mei Li, et al.
Cancers (2023) Vol. 15, Iss. 2, pp. 533-533
Open Access | Times Cited: 81
Page 1 - Next Page

Scroll to top